NOVATO, Calif.–(BUSINESS WIRE)–QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that Barry Roseman, MD, FACS, is serving as a Senior Medical Advisor to the company.
Dr. Roseman’s engagement includes clinical implementation of the QT Imaging technology in a busy breast diagnostic and screening center. This installation is expected to support physician training, workflow integration, patient access, and ongoing collection of real-world clinical, operational, financial, patient, and provider experiences.
“Dr. Roseman’s involvement with QT Imaging is substantially more than a traditional advisory role, and we are honored to enter into this new relationship with such an esteemed professional,” commented Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “Dr. Roseman has a deep, firsthand understanding of the limitations and challenges women face throughout the breast imaging and diagnostic pathway. His decision to deploy the QTI Breast Acoustic CT scanner within his own clinical environment is a strong validation of our mission to provide women with a safer, more comfortable, and clinically meaningful breast imaging solution.”
During his career, Dr. Roseman has treated more than 5,000 breast cancer patients and currently operates Advanced Breast Care / Surgical Oncology of North Georgia, a breast imaging and diagnostic center focused on comprehensive breast care. His practice includes breast imaging, screening and diagnostic breast ultrasound, image-guided biopsy, breast surgical oncology, and the long-term management of patients with breast cancer and complex breast problems.
“In my clinical practice I constantly see the challenges that patients face with abnormal imaging results, and the increasing awareness of breast density as an important factor in breast cancer screening,” said Dr. Roseman. “We are also beginning to understand how to personalize screening based on patients’ risk. I believe that new technologies that can add valuable imaging information while prioritizing patient comfort are critically important, and warrant serious evaluation in clinical practice. I am hopeful that QT Imaging will help fulfill these goals.”
QT Imaging believes that physician-led adoption remains one of the most important drivers of innovation in breast imaging. The company expects Dr. Roseman’s clinical experience and operational implementation of QTscan to contribute meaningfully to the evolution of imaging workflows, interpretation standards, and future precision breast oncology applications.
QT Imaging is a radiation-free, compression-free, true 3D breast-imaging technology designed to provide quantitative breast imaging information through advanced ultrasound tomography. The company believes the platform may play an important role as an adjunct imaging modality, particularly for women with dense breast tissue.
Dr. Roseman is a surgical oncologist and breast surgeon with more than 25 years of experience treating breast cancer and breast disease. He completed his residency in general surgery at the University of California San Francisco and his surgical oncology fellowship at MD Anderson Cancer Center. He is board certified in general surgery and is a Fellow of the American College of Surgeons.
About QT Imaging
QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit www.qtimaging.com and follow us on LinkedIn.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the implementation of QT Imaging’s Breast Acoustic CT system in a clinical center, use of the system for imaging, including for dense breasts, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging’s expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging’s assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts
Investors
Alliance Advisors IR
Bruce Voss
[email protected]
310-691-7104
Media
Alliance Advisors IR
Fatema Bhabrawala
[email protected]
647-620-5002
